Cereno Scientific
Tove Bergenholt is currently working as the COO & Communication Director at MSC Nordics, a strategy & communication consultancy specialized in the Nordic Life Science industry. She also holds consultancy roles in communications & investor relations at IRLAB Therapeutics and Cereno Scientific. Prior to this, she worked as a Communication Manager at Monocl Strategy Services and held positions at W2O Group and WCG. She has a background in digital business management, informatics, business administration, and web development from various universities. In addition, she has experience as a substitute teacher at a comprehensive school in Göteborgs Stad.
This person is not in any teams
Cereno Scientific
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.